Broad-Spectrum Antiviral NV-387 Phase II Clinical Trial Responding to MPox Pandemic in Africa, Readying to Tackle Bird Flu ...

Genomic and epidemiologic data suggest that the rapid spread of mpox clade Ib in the Democratic Republic of the Congo (DRC) ...

NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) declared today that it is ready to fight the bird flu with its revolutionary broad-spectrum antiviral drug NV-387, a drug that the Bird Flu ...

Plus: A shift in bird flu strategy, a new vaccine for meningococcal disease, a new AI genomics model from Nvidia and more.

NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today announced that it has engaged a Clinical Research Organization (CRO) to conduct a Phase II clinical trial advancing its broad-spectrum ...

MPox disease, caused by the human Mpox virus (hMPXV) has been causing a regional ... activity against an orthopoxvirus in an animal model that is considered an important model to establish ...

Shelton, Connecticut Thursday, February 13, 2025, 16:00 Hrs [IST] ...

My message to the leaders assembling here in Munich is clear: global health security will never be a zero-sum game.

There’s a lot of excitement about the potential for what DeepSeek’s highly efficient AI can do. But it has a problem: It ...